Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination

Basit Öğe Kaydı
dc.contributor.authorSanli, U. A.
dc.contributor.authorGorumlu, G.
dc.contributor.authorErten, C.
dc.contributor.authorGul, M. K.
dc.contributor.authorCengiz, E.
dc.contributor.authorKucukzeybek, Y.
dc.contributor.authorKaraca, B.
dc.contributor.authorAtmaca, H.
dc.contributor.authorUzunoglu, S.
dc.contributor.authorKarabulut, B.
dc.contributor.authorUslu, R.
dc.date.accessioned2019-10-27T20:48:20Z
dc.date.available2019-10-27T20:48:20Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description.abstractPossible synergistic cytotoxic and apoptotic effects of gossypol with zoledronic acid on DU-145 cells were explored, along with the rationale behind any observed synergism due to the different apoptotic proteins involved. XTT cell proliferation assay was used to assess the cytotoxicity, and DNA fragmentation and caspase 3/7 activity were measured to verify apoptosis. Human Apoptosis Array was used to evaluate apoptotic proteins. The synergistic cytotoxic combination treatment had a versatile effect on apoptotic proteins, through inhibition of anti-apoptotic proteins (including cIAP-1, cIAP-2, survivin, livin, claspin, p53, p21, PON-2 and heat shock proteins) and concurrently the induction of pro-apoptotic proteins (Bad, Bax, Fas, FADD, cleaved caspase-3 and p27). Both drugs had a minimal toxicity profile comparing to cytotoxic agents. Combination treatments targeting many pivotal apoptosis-related proteins may be a rationale option for treatment of prostate cancer. (C) 2009 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.cellbi.2009.08.006en_US
dc.identifier.endpage1172en_US
dc.identifier.issn1065-6995
dc.identifier.issn1095-8355
dc.identifier.issue11en_US
dc.identifier.pmid19716895en_US
dc.identifier.startpage1165en_US
dc.identifier.urihttps://doi.org/10.1016/j.cellbi.2009.08.006
dc.identifier.urihttps://hdl.handle.net/11454/42694
dc.identifier.volume33en_US
dc.identifier.wosWOS:000271517400006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofCell Biology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGossypolen_US
dc.subjectZoledronic aciden_US
dc.subjectSynergyen_US
dc.subjectApoptosisen_US
dc.subjectDU-145en_US
dc.subjectProstateen_US
dc.titleTargeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combinationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu